CAMBRIDGE, UK - AstraZeneca (NASDAQ:AZN) has announced that its recent PACIFIC-2 Phase III trial, which tested the efficacy of Imfinzi in combination with platinum-based chemoradiotherapy (CRT), did not meet the primary endpoint of progression-free survival (PFS) in patients with unresectable Stage III non-small cell lung cancer (NSCLC). Despite this outcome, the treatment regimen reaffirmed its position as the standard of care for this condition.
The trial, under the leadership of Jeffrey D. Bradley, MD from Penn Medicine in Philadelphia, aimed to explore the benefits of administering Imfinzi concurrently with CRT. While it did not reach statistical significance for PFS, it was noted that the safety and tolerability profiles were consistent with previously known data, including observed increased infection rates during concurrent treatment.
Susan Galbraith, Executive Vice President of Oncology R&D at AstraZeneca, expressed continued commitment to advancing immunotherapy for lung cancer patients across various treatment settings. AstraZeneca is actively conducting trials to evaluate Imfinzi's effectiveness in early stages of lung cancer.
Imfinzi remains the only approved immunotherapy and global standard of care in the curative-intent setting for unresectable Stage III NSCLC patients whose disease has not progressed following chemoradiation therapy. AstraZeneca's strategy includes early-stage disease detection and a comprehensive portfolio of leading lung cancer medicines.
The company has been at the forefront of integrating immunotherapy into clinical areas with high unmet medical needs and maintains a diverse immunotherapy (IO) portfolio. As a founding member of the Lung Ambition Alliance, AstraZeneca's mission encompasses redefining cancer care with the ultimate goal of eradicating cancer as a cause of death. Their portfolio boasts a range of treatments including Tagrisso, Iressa, Enhertu, datopotamab deruxtecan, and Orpathys.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.